Skip Main Navigation
Page Content
This event has ended

2013 Chabner Colloquium "Collaboration in Cancer Drug Trials"

STO and MGH

Ends Tuesday, October 29, 2013 at 3:30 PM (EDT)

2013 Chabner Colloquium "Collaboration in Cancer Drug...

Registration Information

Registration Type Sales End Price Fee Quantity
DF/HCC Clinician/Researcher Ended $150.00 $0.00
Clinician/Researcher outside of DF/HCC Network Ended $225.00 $0.00
Residents, Fellows*, Students, Patient Advocates, Support Group Leaders, Patients/Caregivers, Media Ended $100.00 $0.00
Industry Personnel Ended $300.00 $0.00

Share 2013 Chabner Colloquium "Collaboration in Cancer Drug Trials"

Event Details

STO logo Banner

Overview:
The Society for Translational Oncology (STO) and the Massachusetts General Hospital Cancer Center (MGHCC), will host the 2013 Chabner Colloquium at Starr Center at Schepens Eye Research Institute in Boston, Massachusetts. 

 This meeting will focus on topics that bring cancer biology to clinical application:

  • New targets and targeted agents
  • Strategies for profiling and selection of patients for targeted drug trials
  • Biomarkers and animal models to guide clinical development 

Meeting Location: 

Starr Center at Schepens Eye Research Institute

185 Cambridge Street, 2nd Floor

Boston, MA 20114


Parking Information is available here

Directions are available here

 

Brief Agenda:

Monday, October 28, 2013

7:00 am - Registration and continental breakfast

7:55 am - Welcome and introductions

8:00 am - 5:00pm: Meeting

5:00 pm - Adjourn


Tuesday, October 29, 2013

7:00 am - Registration and continental breakfast

7:55 am - Welcome and introductions

8:00 am - 3:30 pm: Meeting

3:30 pm - Adjourn

 

Scroll to the bottom for the full version of the agenda.


Target Audience

This activity is designed to meet the educational needs of physicians and scientists in academic and practice settings who wish to advance their knowledge of the research into new treatments and improve their competence in the care of patients with cancer.

CME Accreditation

This activity is planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the Joint Sponsorship of the Society for Translational Oncology and the Massachusetts General Hospital. The Society for Translational Oncology is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

STO is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. This live symposium will be designated for a maximum of 12 AMA PRA Category 1 Credit(s)™. Participants should only claim credit commensurate with their participation in the symposium. 


Registration

Registration includes meeting materials, abstract book, breakfast, breaks, beverages, and lunch both days*.

One day rate is now available.
Use the promotion code 1DAY when you checkout. 

* Effective August 1, 2013, The Centers for Medicare & Medicaid Services (CMS) requires reporting of any direct or indirect payments made to any US Healthcare Professional by pharmaceutical and device manufacturers and applicable group purchasing organizations (GPOs) under its Open Payments program.

In order to comply with the requirements of those companies who have provided support for this CME activity, all food and beverage costs associated with this activity have been covered directly by the participant registration fee. Therefore, there has been no indirect payment or transfer of value for your attendance at this meeting. No data regarding your participation at this meeting will be reported to CMS.  

 

Fellows - please provide an e-mail letter from your director or advisor confirming your status. 

 

Refunds:
Registrants are eligible for a registration refund if the refund is requested in writing prior to October 15, 2013 and will incur a processing fee of $50. There are no registration refunds after October 16, 2013.


 

Conference Learning Objectives

Please note that these preliminary conference learning objectives, based on the identified gaps, will be further refined with the assistance of the course chair. In addition, an individual learning objective per presentation will be designed with the speaking faculty and its achievement measured following the meeting. 

At the conclusion of this meeting, participants will be better able to:

  • Discuss the integration of tumor profiling, non-invasive biomarker development, and use of animal models into trial design for molecular-based drug development.
  • Describe the technical hurdles for the translation of molecular-based drug development into agents for routine oncologic practice.
  • Evaluate the potential of molecular-based drug development for improving results of treatment of common and rare tumors.

 

CME Credit
In order to receive CME credit, learners must sign-in on the day of the activity, review the CME information (accreditation, learning objectives, faculty disclosures, etc.), and attend the CME activity. Learners will be asked to complete an electronic activity evaluation following the meeting and indicate the number of credit hours claimed. Certificates will be provided upon successful completion of the evaluation.


PRELIMINARY AGENDA 

Monday, October 28, 2013

Registration opens at 7:00 a.m.

7:00 a.m. – 8:00 a.m. Continental Breakfast

Dealing with resistance to Targeted Therapy – Bruce Chabner, MGH, Moderator

8:00 a.m.

Jeff Engelman (MGH)

Defining resistance to targeted drugs

8:45 a.m

Lecia Sequist (MGH)

EGFR mutant lung cancer:  new drugs

9:30 a.m.

Alice Shaw (MGH)      

Second Generation ALK Inhibitors in NSCLC

  10:15a.m. – 10:30 a.m.  Break 

 The Biology of Unique Tumors – Nick Dyson, MGH, Moderator 

10:30 a.m.

Michael Kelley (Duke)

The role of brachyury in notochordal and non-notochordal malignancy 

11:15 a.m.

Johnathan Whetstine (MGH)

Chromatin modulators provide a new insight into cancer genomics 

  12:00 p.m. – 1:00 p.m.   lunch break

  Drug Development Based on New signaling Pathways – Timothy Graubert, MGH, Moderator 

1:00 p.m

Louis Staudt  (NCI)

New lymphoma therapies inspired by functional and structural genomics

2:00 p.m.

Jesse Smith (Epizyme)

Protein methyltransferase inhibitors as personalized cancer therapeutics 

  3:00 p.m. – 3:15 p.m.    Break

Fellows forum – Joe Bertino, Moderator

3:15 p.m.

Andrew Lane

Histone H3K27 demethylases as a therapeutic target in polysomy 21 leukemia

3:35 p.m.

Ami Bhatt

Bacterial genomics in transplant-related colitis

3:55 p.m.

Jonathan Carlson

“Click” Chemistry in vivo – New Tools for Molecular Imaging

4:15 p.m.

Anna Farago

Leveraging genetically engineered mouse models of small cell lung cancer for advanced therapeutic studies

4:35 p.m.

Franklin Huang

TERT promoter mutations in cancer

   5:00 p.m.         Adjourn Day 1

Tuesday, October 29, 2013

Registration opens at 7:00 a.m.

7:00 a.m. – 8:00 a.m. Continental Breakfast

Melanoma – Biology and Treatment, 2013 – David Ryan, MGH, Moderator

8:00 a.m.

Keith Flaherty (MGH)

Next steps in melanoma treatment

8:45 a.m.

David Fisher (MGH)

Multiple roles of MITF in melanoma and melanocyte biology

9:30a.m.

Dejan Juric (MGH)

PI3KCA as a target in breast cancer

  10:00 a.m.              Break

  Stem Cells and Circulating tumor Cells – David Fisher, MGH, Moderator 

10:15 a.m.

Jon Pachter (Verastem)

Stem cell targeted therapy

11:00 a.m.

David Ting (MGH)

Molecular analysis of CTCs

11:30 a.m.

George Daley (DFCI)

Molecular regulation of normal and malignant stem cells

  12:15 p.m. – 1:00 p.m. box lunch 

 Prostate Cancer: Progress and Promise, Part 4 – Dror Michaelson, Moderator  

1:15 p.m.

Welcome and introductions

 

1:20 p.m.

Rick Lee (MGH)

CTC developments

1:45 p.m.

Mary Ellen Taplin (Dana Farber)

Neoadjuvant therapy

2:10 p.m.

Matthew Smith (MGH)

Novel agents in advanced disease

2:35 p.m.

Levi Garraway (Broad Institute)

Genomic analyses in prostate cancer

3:00 p.m.

Panel Discussion

 

3:30 p.m.

Summary and adjourn

 


Acknowledgements

STO gratefully acknowledges educational grants received from: 

Amgen

Lilly

Merrimack Pharmaceuticals

Novartis Oncology

Pfizer

Sanofi Oncology


STO has applied for educational grants from multiple sources and supporting company name(s) will be added when confirmed. 

 

Hotel Information

If you are attending the conference from out of town, please plan to make your own hotel arrangements. The hotel closest to the meeting location is:

Wyndham Boston Beacon Hill
5 Blossom Street
Boston, MA 02114

Phone: 617-742-7630

Have questions about 2013 Chabner Colloquium "Collaboration in Cancer Drug Trials"? Contact STO and MGH

When & Where


The Starr Center at Schepens Eye Research Institute
185 Cambridge Street
Boston, MA 02114

Ends Tuesday, October 29, 2013 at 3:30 PM (EDT)


  Add to my calendar

Please log in or sign up

In order to purchase these tickets in installments, you'll need an Eventbrite account. Log in or sign up for a free account to continue.